Hironaga Satake

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 21

Top Topics

Acute Myeloid Leukemia

Top Venues

Surgical case reports

Nature communications

Journal of clinical medicine

Japanese journal of clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Yoshitaka Honma, Nobuya Monden, Keisuke Yamazaki, Satoshi Kano, Hironaga Satake, Shigenori Kadowaki, Yoshitaka Utsumi, Tomohiko Nakatogawa, Ryo Takano, Koji Fujii, Yosuke Koroki, Junya Aoyama, Shohei Ouchi, Tetsuro Ogawa, Sharon McCarthy, Sabine D Brookman-May, Suneel D Mundle, Jinhui Li, Daksh Thaper, Toshitaka Nagao, Yuichiro Tada
Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase 2 Nonrandomized Clinical Trial, YATAGARASU. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Yoshiaki Nakamura, Hiroshi Ozaki, Makoto Ueno, Yoshito Komatsu, Satoshi Yuki, Taito Esaki, Hiroya Taniguchi, Yu Sunakawa, Kensei Yamaguchi, Ken Kato, Tadamichi Denda, Tomohiro Nishina, Naoki Takahashi, Taroh Satoh, Hisateru Yasui, Hironaga Satake, Eiji Oki, Takeshi Kato, Takashi Ohta, Nobuhisa Matsuhashi, Masahiro Goto, Naohiro Okano, Koushiro Ohtsubo, Kentaro Yamazaki, Riu Yamashita, Naoko Iida, Mihoko Yuasa, Hideaki Bando, Takayuki Yoshino
Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors. Nature medicine (2024)
Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Yoshinori Kagawa, Tadamichi Denda, Manabu Shiozawa, Taroh Satoh, Tomohiro Nishina, Masahiro Goto, Naoki Takahashi, Takeshi Kato, Hideaki Bando, Kensei Yamaguchi, Takayuki Yoshino
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy. Nature communications 15 (1) (2024)
Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Yoshinori Kagawa, Tadamichi Denda, Manabu Shiozawa, Taroh Satoh, Tomohiro Nishina, Masahiro Goto, Naoki Takahashi, Takeshi Kato, Hideaki Bando, Kensei Yamaguchi, Takayuki Yoshino
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy. Nature communications 15 (1) (2024)
Yoshitaka Honma, Nobuya Monden, Keisuke Yamazaki, Satoshi Kano, Hironaga Satake, Shigenori Kadowaki, Yoshitaka Utsumi, Tomohiko Nakatogawa, Ryo Takano, Koji Fujii, Yosuke Koroki, Junya Aoyama, Shohei Ouchi, Tetsuro Ogawa, Sharon McCarthy, Sabine D Brookman-May, Suneel D Mundle, Jinhui Li, Daksh Thaper, Toshitaka Nagao, Yuichiro Tada
Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Yoshinori Kagawa, Tadamichi Denda, Manabu Shiozawa, Taroh Satoh, Tomohiro Nishina, Masahiro Goto, Naoki Takahashi, Takeshi Kato, Hideaki Bando, Kensei Yamaguchi, Takayuki Yoshino
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy. Nature communications 15 (1) (2024)
Toshinori Kobayashi, Yuki Matsui, Hisanori Miki, Masahiko Hatta, Mitsuaki Ishida, Hironaga Satake, Mitsugu Sekimoto
Case report: administration of immune checkpoint inhibitor for SMARCB1 (INI1)-negative rhabdoid carcinoma with microsatellite instability (MSI)-high in the right colon. Surgical case reports 9 (1) (2023)
Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, Hiroya Taniguchi, Hideaki Bando, Manabu Shiozawa, Tomohiro Nishina, Hisateru Yasui, Yoshinori Kagawa, Naoki Takahashi, Tadamichi Denda, Taito Esaki, Hiasto Kawakami, Hironaga Satake, Atsuo Takashima, Nobuhisa Matsuhashi, Takeshi Kato, Chiharu Asano, Yukiko Abe, Shogo Nomura, Takayuki Yoshino
Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study. Cancer medicine (2023)
Toshinori Kobayashi, Yuki Matsui, Hisanori Miki, Masahiko Hatta, Mitsuaki Ishida, Hironaga Satake, Mitsugu Sekimoto
Case report: administration of immune checkpoint inhibitor for SMARCB1 (INI1)-negative rhabdoid carcinoma with microsatellite instability (MSI)-high in the right colon. Surgical case reports 9 (1) (2023)
Hironaga Satake, Keun-Wook Lee, Hyun Cheol Chung, Jeeyun Lee, Kensei Yamaguchi, Jen-Shi Chen, Takaki Yoshikawa, Kenji Amagai, Kun-Huei Yeh, Masahiro Goto, Yee Chao, Ka-On Lam, Shi Rong Han, Shinichi Shiratori, Sukrut Shah, Kohei Shitara
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062. Japanese journal of clinical oncology 53 (3) (2023)
Toshinori Kobayashi, Yuki Matsui, Hisanori Miki, Masahiko Hatta, Mitsuaki Ishida, Hironaga Satake, Mitsugu Sekimoto
Case report: administration of immune checkpoint inhibitor for SMARCB1 (INI1)-negative rhabdoid carcinoma with microsatellite instability (MSI)-high in the right colon. Surgical case reports 9 (1) (2023)
Toshinori Kobayashi, Yuki Matsui, Hisanori Miki, Masahiko Hatta, Mitsuaki Ishida, Hironaga Satake, Mitsugu Sekimoto
Case report: administration of immune checkpoint inhibitor for SMARCB1 (INI1)-negative rhabdoid carcinoma with microsatellite instability (MSI)-high in the right colon. Surgical case reports 9 (1) (2023)
Tatsuki Ikoma, Mototsugu Shimokawa, Toshihiko Matsumoto, Shogen Boku, Tomoyo Yasuda, Nobuhiro Shibata, Yusuke Kurioka, Masahiro Takatani, Tetsuji Nobuhisa, Tsutomu Namikawa, Hiroyuki Kitagawa, Kazuhiro Hanazaki, Keitaro Doi, Takanobu Shimada, Takehiko Tsumura, Hiroyuki Marusawa, Seichiro Kanaya, Shuko Morita, Tetsurou Inokuma, Hiroki Nagai, Hisateru Yasui, Hironaga Satake
Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab. Cancer immunology, immunotherapy : CII (2022)
Shogen Boku, Hironaga Satake, Takashi Ohta, Seiichiro Mitani, Kentaro Kawakami, Yozo Suzuki, Toshihiko Matsumoto, Tetsuji Terazawa, Eiki Yamazaki, Hiroko Hasegawa, Tatsuki Ikoma, Mamoru Uemura, Toshifumi Yamaguchi, Atsushi Naito, Yasunobu Ishizuka, Yukinori Kurokawa, Daisuke Sakai, Hisato Kawakami, Toshio Shimokawa, Toshimasa Tsujinaka, Takeshi Kato, Taroh Satoh, Yoshinori Kagawa
TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III BRAF V600E-mutated colorectal cancer. Future oncology (London, England) (2022)
Tatsuki Ikoma, Toshihiko Matsumoto, Yusuke Kurioka, Masahiro Takatani, Hiroki Nagai, Yusuke Matsumoto, Hironaga Satake, Hisateru Yasui
Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy. Journal of clinical medicine 11 (20) (2022)
Hironaga Satake, Keun-Wook Lee, Hyun Cheol Chung, Jeeyun Lee, Kensei Yamaguchi, Jen-Shi Chen, Takaki Yoshikawa, Kenji Amagai, Kun-Huei Yeh, Masahiro Goto, Yee Chao, Ka-On Lam, Shi Rong Han, Shinichi Shiratori, Sukrut Shah, Kohei Shitara
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062. Japanese journal of clinical oncology (2022)
Toshihiko Matsumoto, Shogo Yamamura, Tatsuki Ikoma, Yusuke Kurioka, Keitaro Doi, Shogen Boku, Nobuhiro Shibata, Hiroki Nagai, Takanobu Shimada, Takao Tsuduki, Takehiko Tsumura, Masahiro Takatani, Hisateru Yasui, Hironaga Satake
Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study. Journal of clinical medicine 11 (8) (2022)
Akira Ooki, Satoshi Morita, Akihito Tsuji, Shigeyoshi Iwamoto, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Suto, Yojiro Hashiguchi, Taichi Yabuno, Masahiko Ando, Junichi Sakamoto, Kensei Yamaguchi
Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. Cancer medicine 9 (24) (2020)
Hironaga Satake, Akihito Tsuji, Masato Nakamura, Masaaki Ogawa, Takeshi Kotake, Yukimasa Hatachi, Hisateru Yasui, Akinori Takagane, Yoshihiro Okita, Kumi Nakamura, Toshihide Onikubo, Masahiro Takeuchi, Masashi Fujii
Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study. International journal of clinical oncology 23 (3) (2018)
Hironaga Satake, Tamotsu Sagawa, Koshi Fujikawa, Yukimasa Hatachi, Hisateru Yasui, Masahito Kotaka, Takeshi Kato, Akihito Tsuji
Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane. Cancer chemotherapy and pharmacology 82 (5) (2018)
Tomohiro Yabushita, Hironaga Satake, Hayato Maruoka, Mari Morita, Daisuke Katoh, Yoshimitsu Shimomura, Satoshi Yoshioka, Takeshi Morimoto, Takayuki Ishikawa
Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia. Leukemia & lymphoma 59 (9) (2017)